公开(公告)号：US20220098303A1

公开(公告)日：2022-03-31

申请号：US17426695

申请日：2020-01-31

Applicant: GlaxoSmithKline Intellectual Property Development Limited

Inventor： Swethajit Biswas ,  Nicola A. JACKSON ,  Elaine Marie PAUL ,  Herbert STRUEMPER ,  Joanna OPALINSKA

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: Disclosed herein are combinations of an antigen binding protein that binds BCMA with an antigen binding protein that bind to an immunomodulatory agent, such as PD-1 or OX40, pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said combinations, including uses in cancer.

公开(公告)号：US20210395367A1

公开(公告)日：2021-12-23

申请号：US17287144

申请日：2019-10-21

Applicant: Glaxosmithkline Intellectual Property Development Limited

Inventor： Elaine Marie PAUL ,  Patrick MAYES ,  Catherine E. ELLIS ,  Jessica KATZ

IPC: C07K16/28 ,  A61P35/00

Abstract: The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg.

公开(公告)号：US20210324081A1

公开(公告)日：2021-10-21

申请号：US17287358

申请日：2019-10-21

Applicant: GlaxoSmithkline Intellectual Property Development Limited ,  MSD International GmbH

Inventor： Elaine Marie PAUL ,  Patrick MAYES ,  Catherine E. ELLIS ,  Jessica KATZ

IPC: C07K16/28 ,  A61K9/00 ,  A61P35/00 ,  A61K39/395

Abstract: The present invention relates to a method of treating cancer comprising administering to the human an ICOS binding protein or antigen binding portion thereof at a dose of about 0.08 mg to about 240 mg and administering to the human a PD1 antagonist.